FIGURE 1.

Postulated mechanisms by which the mostly used anti‐diabetic medications may favor or prevent hepatocarcinogenesis. Metformin, TZDs, SGLT2 inhibitors, GLP1‐Ras, and DDP4‐inhibitors may protect from HCC development and growth, whereas sulphonylureas and insulin favor HCC development